Abstract |
This study evaluated the efficacy and tolerability of new extended-release (ER) tolterodine for the treatment of overactive bladder in women. In this subpopulation analysis of a double-blind multicenter trial, 1235 female patients were randomized to oral therapy with tolterodine ER 4 mg once daily (n=417), tolterodine IR 2 mg twice daily (n=408) or placebo (n=410) for 12 weeks. Both formulations reduced the mean number of urge incontinence episodes per week (both P=0.001 vs placebo); tolterodine ER was more effective than tolterodine IR (P=0.036). Both formulations significantly improved all other micturition chart variables compared to placebo. Dry mouth was the most common adverse event. There were no safety concerns. Toltrodine ER 4 mg once daily is effective and well tolerated in the treatment of women with overactive bladder, and reduces urge incontinence episodes more than the existing IR twice-daily formulation.
|
Authors | S Swift, A Garely, T Dimpfl, C Payne, Tolterodine Study Group |
Journal | International urogynecology journal and pelvic floor dysfunction
(Int Urogynecol J Pelvic Floor Dysfunct)
Vol. 14
Issue 1
Pg. 50-4; discussion 54-5
(Feb 2003)
England |
PMID | 12601517
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzhydryl Compounds
- Cresols
- Delayed-Action Preparations
- Muscarinic Antagonists
- Phenylpropanolamine
- Tolterodine Tartrate
|
Topics |
- Benzhydryl Compounds
(administration & dosage, therapeutic use)
- Cresols
(administration & dosage, therapeutic use)
- Delayed-Action Preparations
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Middle Aged
- Muscarinic Antagonists
(administration & dosage, therapeutic use)
- Phenylpropanolamine
- Tolterodine Tartrate
- Urinary Bladder Diseases
(drug therapy)
- Urinary Incontinence
(drug therapy)
|